Sanofi agreed to acquire Blueprint for $129.00/share cash ($9.1B equity) plus CVRs of $2 (BLU-808 clinical milestone) and $4 (BLU-808 regulatory milestone), total up to $9.5B. Adds Ayvakit, the only approved therapy for advanced and indolent systemic mastocytosis, plus early-stage immunology pipeline. Completed July 18, 2025.